- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 1, Pages 131
Publisher
MDPI AG
Online
2021-01-04
DOI
10.3390/cancers13010131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
- (2020) Ryoji Kato et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
- (2020) Olga Bednova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
- (2020) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Four Immune Subtypes in Bladder Cancer Based on Immune Gene Sets
- (2020) Chaozhi Tang et al. Frontiers in Oncology
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis
- (2019) Chiara Ciccarese et al. SEMINARS IN ONCOLOGY
- Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy
- (2019) Alessia Cimadamore et al. CURRENT DRUG METABOLISM
- PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology
- (2019) Henning Reis et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go
- (2019) Thomas Gevaert et al. Future Oncology
- Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
- (2019) Shahin Jamal et al. JOURNAL OF RHEUMATOLOGY
- Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype
- (2019) Jorge Rebola et al. VIRCHOWS ARCHIV
- DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
- (2019) Thiago Vidotto et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy and urothelial carcinoma: An overview and future prospectives
- (2019) Francesco Pierantoni et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer
- (2019) Alfonso Gómez de Liaño Lista et al. EUROPEAN UROLOGY
- PD-L1 assessment in urothelial carcinoma: a practical approach
- (2019) Markus Eckstein et al. Annals of Translational Medicine
- The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
- (2019) Thomas Powles et al. CANCER TREATMENT REVIEWS
- PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
- (2018) Anjelica Hodgson et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies
- (2018) Francesco Massari et al. CANCER TREATMENT REVIEWS
- Immune checkpoint inhibitors for metastatic bladder cancer
- (2018) Francesco Massari et al. CANCER TREATMENT REVIEWS
- Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
- (2018) Matthew D. Galsky et al. EUROPEAN UROLOGY
- Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer
- (2018) Alessia Cimadamore et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions
- (2018) Aaron Phelan et al. Future Oncology
- Targeting the CD73-adenosine axis in immuno-oncology
- (2018) David Allard et al. IMMUNOLOGY LETTERS
- S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.
- (2018) Peter C. Black et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
- (2018) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
- (2018) Markus Eckstein et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 Antibody Comparison in Urothelial Carcinoma
- (2018) Maud Rijnders et al. EUROPEAN UROLOGY
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- (2017) Sebastien Antoni et al. EUROPEAN UROLOGY
- Tp53 and its potential therapeutic role as a target in bladder cancer
- (2017) Chiara Ciccarese et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
- (2017) Thomas Gevaert et al. SEMINARS IN CANCER BIOLOGY
- The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
- (2017) Andrea Botticelli et al. Oncotarget
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Biomarkers for immunotherapy in bladder cancer: a moving target
- (2017) David H. Aggen et al. Journal for ImmunoTherapy of Cancer
- Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)—Interim analysis on safety.
- (2017) Susana Hernando Polo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
- (2016) Christoph Oing et al. JOURNAL OF UROLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging role of immunotherapy in urothelial carcinoma—Advanced disease
- (2016) Matthew Zibelman et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
- (2016) R. F. Sweis et al. Cancer Immunology Research
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
- (2015) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Bladder Cancer: Molecular Determinants of Personalized Therapy
- (2015) Antonio Lopez-Beltran et al. CURRENT DRUG TARGETS
- Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
- (2015) Sheila F. Faraj et al. UROLOGY
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapeutic Drugs may be Used to Enhance the Killing Efficacy of Human Tumor Antigen Peptide-specific CTLs
- (2008) Pierpaolo Correale et al. JOURNAL OF IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now